TrialDiabetes, obesity & metabolism2017

Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes.

Per Lundkvist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.